Interstitial Lung Disease in Systemic Sclerosis: A Simple Staging System
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
RATIONALE: In interstitial lung disease complicating systemic sclerosis (SSc-ILD), the optimal prognostic use of baseline pulmonary function tests (PFTs) and high-resolution computed tomography (HRCT) is uncertain. OBJECTIVES: To construct a readily applicable prognostic algorithm in SSc-ILD, integrating PFTs and HRCT. METHODS: The prognostic value of baseline PFT and HRCT variables was quantified in patients with SSc-ILD (n = 215) against survival and serial PFT data. MEASUREMENTS AND MAIN RESULTS: Increasingly extensive disease on HRCT was a powerful predictor of mortality (P < 0.0005), with an optimal extent threshold of 20%. In patients with HRCT extent of 10-30% (termed indeterminate disease), an FVC threshold of 70% was an adequate prognostic substitute. On the basis of these observations, SSc-ILD was staged as limited disease (minimal disease on HRCT or, in indeterminate cases, FVC >or= 70%) or extensive disease (severe disease on HRCT or, in indeterminate cases, FVC < 70%). This system (hazards ratio [HR], 3.46; 95% confidence interval [CI], 2.19-5.46; P < 0.0005) was more discriminatory than an HRCT threshold of 20% (HR, 2.48; 95% CI, 1.57-3.92; P < 0.0005) or an FVC threshold of 70% (HR, 2.11; 95% CI, 1.34-3.32; P = 0.001). The system was evaluated by four trainees and four practitioners, with minimal and severe disease on HRCT defined as clearly < 20% or clearly > 20%, respectively, and the use of an FVC threshold of 70% in indeterminate cases. The staging system was predictive of mortality for all scorers, with prognostic separation higher for practitioners (HR, 3.39-3.82) than trainees (HR, 1.87-2.60). CONCLUSIONS: An easily applicable limited/extensive staging system for SSc-ILD, based on combined evaluation with HRCT and PFTs, provides discriminatory prognostic information.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2005) · PubMed · Cited by 7,011
Preliminary criteria for the classification of systemic sclerosis (scleroderma)
Masi, A. T., & Subcommittee For Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230510 · Cited by 4,898
Cyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Survival Model Predictive Accuracy and ROC Curves
Heagerty, P. J., & Zheng, Y. (2005) · Biometrics · doi:10.1111/j.0006-341x.2005.030814.x · Cited by 1,464
Predicting Survival in Idiopathic Pulmonary Fibrosis
KING, T. E., TOOZE, J. A., SCHWARZ, M. I., BROWN, K. R., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.7.2003140 · Cited by 853
Bouros, D., Wells, A. U., Nicholson, A. G., Colby, T. V., Polychronopoulos, V., Pantelidis, P., Haslam, P. L., Vassilakis, D. A., Black, C. M., & du Bois, R. M. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2106012 · Cited by 820
Self-citationFERRI, C., VALENTINI, G., COZZI, F., SEBASTIANI, M., MICHELASSI, C., LA MONTAGNA, G., BULLO, A., CAZZATO, M., TIRRI, E., STORINO, F., et al. (2002) · Medicine · doi:10.1097/00005792-200203000-00004 · Cited by 764
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
Raghu, G., Brown, K. K., Bradford, W. Z., Starko, K., Noble, P. W., Schwartz, D. A., & King, T. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030511 · Cited by 652 · cited 1×
“Mortality, disease progression (‘‘time to decline’’ in either FVC levels of >10% from baseline or DLCO levels of >15% from baseline) and ‘‘progression-free survival’’ were quantified from the date of HRCT, as previously described (10, 13 ) (see online supplement).”
MethodSevere restrictive lung disease in systemic sclerosis
Steen, V. D., Conte, C., Owens, G. R., & Medsger, T. A. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370903 · Cited by 526
Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Roth, M. D., Furst, D. E., Silver, R. M., Goldin, J., Arriola, E., Strange, C., Bolster, M. B., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200702-326oc · Cited by 464
Desai, S. R., Veeraraghavan, S., Hansell, D. M., Nikolakopolou, A., Goh, N. S. L., Nicholson, A. G., Colby, T. V., Denton, C. P., Black, C. M., du Bois, R. M., et al. (2004) · Radiology · doi:10.1148/radiol.2322031223 · Cited by 394
Self-citationSCUSSEL-LONZETTI, L., JOYAL, F., RAYNAULD, J.-P., ROUSSIN, A., RICH, É., GOULET, J.-R., RAYMOND, Y., & SENÉCAL, J.-L. (2002) · Medicine · doi:10.1097/00005792-200203000-00005 · Cited by 361
Watters, L. C., King, T. E., Schwarz, M. I., Waldron, J. A., Stanford, R. E., & Cherniack, R. M. (1986) · American Review of Respiratory Disease · doi:10.1164/arrd.1986.133.1.97 · Cited by 266
Goh, N. S. L., Veeraraghavan, S., Desai, S. R., Cramer, D., Hansell, D. M., Denton, C. P., Black, C. M., du Bois, R. M., & Wells, A. U. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22696 · Cited by 177
Self-citationPredictors of end stage lung disease in a cohort of patients with scleroderma
Morgan, C., Knight, C., Lunt, M., Black, C. M., & Silman, A. J. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.2.146 · Cited by 128
Self-citationShigeyama (2000) · doi:10.1002/1529-0131(200011)43:11
Cited by
Denton, C. P., & Khanna, D. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30933-9 · Cited by 2,212
Self-citationNintedanib for systemic sclerosis–associated interstitial lung disease
Distler, O., Highland, K. B., Gahlemann, M., Azuma, A., Fischer, A., Mayes, M. D., Raghu, G., Sauter, W., Girard, M., Alves, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903076 · Cited by 1,647
Self-citationAllanore, Y., Simms, R., Distler, O., Trojanowska, M., Pope, J., Denton, C. P., & Varga, J. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.2 · Cited by 876
Self-citationWijsenbeek, M., Suzuki, A., & Maher, T. M. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01052-2 · Cited by 539
Self-citationPrediction of Pulmonary Complications and Long‐Term Survival in Systemic Sclerosis
Nihtyanova, S. I., Schreiber, B. E., Ong, V. H., Rosenberg, D., Moinzadeh, P., Coghlan, J. G., Wells, A. U., & Denton, C. P. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38390 · Cited by 460
Self-citation
Metadata
- Authors
- Goh, N. S. L., Desai, S. R., Veeraraghavan, S., Hansell, D. M., Copley, S. J., Maher, T. M., Corte, T. J., Sander, C. R., Ratoff, J., Devaraj, A., Bozovic, G., Denton, C. P., Black, C. M., du Bois, R. M., & Wells, A. U.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-06-01
- Volume
- 177
- Issue
- 11
- Pages
- 1248-1254
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2116531828
- Cited by
- 1,230
- References
- 16
- FWCI
- 24.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.